A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Fazirsiran (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Pharmaceuticals
- 06 Jan 2020 Planned End Date changed from 30 Sep 2019 to 30 Jun 2020.
- 30 Apr 2019 Planned End Date changed from 28 Feb 2019 to 30 Sep 2019.
- 12 Apr 2019 Status changed from active, no longer recruiting to completed, according to an Arrowhead Pharmaceuticals media release.